OR WAIT null SECS
- About Us
- Advertise
- Editorial Information
- Contact Us
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2022 MJH Life Sciences™ and BioPharm International. All rights reserved.
WuXi STA and Regulus Collaborate on microRNA Development and Manufacturing
The agreement follows the recent opening of WuXi STA's oligonucleotide R&D labs in China and the US.
STA Pharmaceutical, a WuXi AppTec group company, and biopharma company Regulus Therapeutics, announced on Feb. 22, 2018 that they have entered into a collaboration focusing on the research and mid-scale non-GMP/cGMP manufacturing of oligonucleotides.
Under the agreement, STA will become the development and manufacturing partner for Regulus' preclinical and clinical programs of microRNA-targeting drugs used to treat a broad range of diseases. Regulus will provide STA with expertise, technical know-how, and training in the field of oligonucleotide scale-up.
STA recently established oligonucleotide R&D labs at both its facilities in San Diego, California and Changzhou, China. The state-of-the-art oligonucleotide GMP manufacturing facility at Changzhou will become operational later in 2018.
Source: WuXi AppTec